Lanthanum Complex with Neridronic Acid: Synthesis and Properties
https://doi.org/10.32362/2410-6593-2019-14-2-70-77
Abstract
Currently, various amino bisphosphonates are widely used in the treatment of many bone diseases. One of the most well-known complex compounds of neridronic acid (6-amino-1-hydroxyhexylidene-1,1- bisphosphonic acid) is sodium neridronate – a bisphosphonate, which is used to treat osteogenesis and Paget's disease. However, there is no data on compounds of neridronic acid with rare earth elements. A new complex of lanthanum with 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (I) was obtained and characterized by various physicochemical methods (chemical analysis, IR spectroscopy, solid-phase 31P NMR spectroscopy, optical microscopy, PCA, DTA). According to the research data the complex I has the composition {La[(H3N-(CH2)5-C(OH)(PO2(OH))2]2(H2O)2}[OH]·H2O and represents the coordination 1D-polymer due to two bridged phosphonic groups with lanthanum atoms in a tetragonal-antiprismatic environment. In a crystal, polymer chains form a 3D-frame porous structure by means of strong hydrogen bonds O─H ··· O and N─H ··· O with endless channels, available to include a variety of inorganic anions or small organic molecules. A study under the microscope showed that the sample is needle crystals (thin rods) of different lengths. The particle size distribution was obtained by laser diffraction, and the average particle size was determined: 50 µm in length and 2.5 µm in thickness.
About the Authors
A. V. Galantsev
MIREA – Russian Technological University, Moscow, 119571, Russia;
LLC Skybiochem, Moscow oblast, Korolev, 141090, Russia
Russian Federation
Russian Federation
Postgraduate Student, K.A. Bolshakov Chair of Chemistry and Technology of Rare and Scattered Elements, Nanoscale and Composite Materials, M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA – Russian Technological University; Deputy General Director of LLC Skybiochem
86, Vernadskogo pr., Moscow, 119571, Russia
2, Mayakovsky St., microdistrict Yubileiny, Korolev, Moscow region, 141090, Russia
D. V. Drobot
MIREA – Russian Technological University, Moscow, 119571, Russia
Russian Federation
Russian Federation
D.Sc. (Chemistry), Professor, K.A. Bolshakov Chair of Chemistry and Technology of Rare and Dispersed Elements, Nanoscale and Composite Materials
86, Vernadskogo pr., Moscow 119571, Russia
P. V. Dorovatovsky
National Research Center Kurchatov Institute, Moscow, 123182, Russia
Russian Federation
Russian Federation
Deputy Head of the Department of Synchrotron Experimental Stations of the Kurchatov Complex of Synchrotron Radiation and Nanotechnologies
1, Akademika Kurchatova sq.., Moscow, 123182, Russia
V. N. Khrustalev
National Research Center Kurchatov Institute, Moscow, 123182, Russia;
Peoples' Friendship University of Russia (RUDN), Moscow, 117198, Russia
Russian Federation
Russian Federation
D.Sc. (Chemistry), Head of the Chair of Inorganic Chemistry, Peoples’ Friendship University of Russia (RUDN), Director of the Joint Institute of Chemical Research of RUDN
6, Miklukho-Maklaya st., Moscow, 117198, Russia
References
1. Loehrer P.J., Williams S.D., Einhorn L.H. Testicular cancer: the quest continues. J. Natl. Cancer Inst. 1988; 80(17):1373-1382. https://doi.org/10.1093/jnci/80.17.1373.
2. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N. Engl. J. Med. 1987; 316:1435-1440. DOI:10.1056/NEJM198706043162302.
3. Bosl G.J., Geller N.L., Bajorin D., Leitner S..P, Yagoda A., Golbey R.B., Scher H., Vogelzang N.J., Auman J., Carey R. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors. J. Clin. Oncol. 1988; 6(8):1231-1238. DOI:10.1200/JCO.1988.6.8.1231.
4. Klenner T., Wingen F., Keppler B.K., Krempien B. and Schmahl D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol. 1990; 116(4):341-350.
5. Galeano A., Berge M.R. and Keppler B.K. Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines. J. Cancer Chemother. Pharmacol. 1992; 30(2):131-138.
6. Ringe J.D., Fardellone P., Kruse H.P., Amling M., van der Geest S.A., Möller G. value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis. Drugs & Aging. 2009; 26(3):241-253. doi:10.2165/00002512-200926030-00005.
7. Simon J.A., Lewiecki E.M., Smith M.E. Patient preference for once-weekly alendronate 70 mg versus oncedaily alendronate 10 mg: a multicenter randomized, openlabel, crossover study. Clin. Ther. 2002; 24(11):1871-1886. https://doi.org/10.1016/S0149-2918(02)80085-6.
8. Ringe J.D., van der Geest S.A.P., Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs & Aging 2006; 23(7):569-578. DOI:10.2165/00002512-200623070-00003.
9. Amghouz Z., García J.R., García-Granda S., Clearfield A., Fernández J.R. Lanthanide phosphonates: Synthesis, thermal stability and magnetic characterization. J. Alloys and Compounds. 2012; 536:S499-S503.
10. Chmielewska E., Kafarski P. Synthetic procedures leading towards aminobisphosphonates. Molecules. 2016; 21(11):1474. https://doi.org/10.3390/molecules21111474.
11. Battye G.G., Kontogiannis L., Johnson O., Powell H.R., Leslie A.G.W. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Cryst. 2011; D67:271-281. https://doi.org/10.1107/S0907444910048675.
12. Evans P. Scaling and assessment of data quality. Acta Cryst. 2006; D62:72-82. https://doi.org/10.1107/S0907444905036693.
13. Sheldrick G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015; C71:3-8. https://doi.org/10.1107/S2053229614024218.
Supplementary files
|
|
1. Fig. 3. Elementary link of the polymer complex I. Bond lengths and valence angles: La1─O1 2.466(3) Å, La1─O4 2.485(3) Å, La1─O2 2.510(3) Å, P1─O1 1.528(3) Å, P1─O2 1.529(3) Å, P2─O4 1.518(3) Å, O1─La1─O4 73.01(9)°, O1─La1─O2 152.85(9)°, O4─La1─O2 76.57(9) | |
| Subject | ||
| Type | Research Instrument | |
View
(53KB)
|
Indexing metadata ▾ | |
|
|
2. Fig. 4. The structure of the coordination polymer I. | |
| Subject | ||
| Type | Research Instrument | |
View
(106KB)
|
Indexing metadata ▾ | |
|
|
3. Fig. 5. Projection of the crystal structure of lanthanum neridronate along the crystallographic b axis. | |
| Subject | ||
| Type | Research Instrument | |
View
(153KB)
|
Indexing metadata ▾ | |
Review
For citations:
Galantsev A.V., Drobot D.V., Dorovatovsky P.V., Khrustalev V.N. Lanthanum Complex with Neridronic Acid: Synthesis and Properties. Fine Chemical Technologies. 2019;14(2):70-77. (In Russ.) https://doi.org/10.32362/2410-6593-2019-14-2-70-77
Views:
919
Email this article 
